Melatonin Prescribing in Assisted Living.
Assisted living
medication
prescribing
Journal
Journal of the American Medical Directors Association
ISSN: 1538-9375
Titre abrégé: J Am Med Dir Assoc
Pays: United States
ID NLM: 100893243
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
17
06
2021
revised:
11
10
2021
accepted:
11
10
2021
pubmed:
12
11
2021
medline:
9
6
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
Aging is associated with sleep problems, which are common among assisted living (AL) residents. More than 40% of residents have insomnia, and almost 70% have a sleep disturbance of some kind. Melatonin to treat sleep disorders has become common among older adults, but its use in AL is unknown, which is concerning because melatonin may have side effects and interfere with other medications. The purpose of this study was to determine the prevalence and correlates of melatonin prescribing in AL, to inform whether changes in care may be indicated. Cross-sectional chart abstracts and interviews. Data were collected in 250 randomly selected AL communities among 5777 residents across 7 states in the United States and weighted to an estimated 4043 communities and 152,719 residents. Charts of residents were abstracted, and AL administrators and health care supervisors were interviewed to obtain information related to case-mix, staffing, and attitudes regarding psychoactive medications. Weighted analyses primarily examined the association of melatonin prescribing with community- and resident-level characteristics. Melatonin was prescribed in 82% of communities, more commonly in those that had a registered nurse or licensed practical nurse on site (+7%, P = .027), and whose health care supervisor was more favorable toward nonpharmacologic practices (+18%, P = .010). On average, 9% of residents were prescribed melatonin, with prescriptions being more common among those diagnosed with dementia (+24%, P = .004); a psychiatric disorder, especially an anxiety disorder (+43%, P = .007); having behavioral expressions; and taking other psychotropics. Coprescribing was common, especially with antidepressants (OR 2.64, 95% CI 1.99, 3.48; P < .001). This study is the first to examine melatonin prescribing in AL, and finds it to be common. Such use may be appropriate if it is as a more suitable replacement for hypnotics. The fact that use varies by organizational characteristics suggests practices may be modifiable. Research examining benefits and side effects of melatonin, overall and in relation to other medications, is indicated to promote better care for AL residents.
Identifiants
pubmed: 34762846
pii: S1525-8610(21)00908-7
doi: 10.1016/j.jamda.2021.10.005
pmc: PMC9097337
mid: NIHMS1756788
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Psychotropic Drugs
0
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1031-1037Subventions
Organisme : NIA NIH HHS
ID : R01 AG050602
Pays : United States
Organisme : NIA NIH HHS
ID : T35 AG038047
Pays : United States
Informations de copyright
Copyright © 2021 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.
Références
Int J Geriatr Psychiatry. 2005 Oct;20(10):956-66
pubmed: 16163747
JAMA. 2008 Jun 11;299(22):2642-55
pubmed: 18544724
Neurol Ther. 2015 Dec;4(2):169-75
pubmed: 26662363
Psychiatr Clin North Am. 2016 Sep;39(3):487-502
pubmed: 27514301
BMC Pharmacol Toxicol. 2013 Feb 08;14:10
pubmed: 23391323
Natl Health Stat Report. 2015 Feb 10;(79):1-16
pubmed: 25671660
J Gerontol B Psychol Sci Soc Sci. 2005 Jul;60(4):S195-204
pubmed: 15980295
Neuroendocrinology. 1987 Aug;46(2):125-30
pubmed: 3114663
Best Pract Res Clin Endocrinol Metab. 2003 Jun;17(2):273-85
pubmed: 12787552
Int Psychogeriatr. 2019 Jun;31(6):837-847
pubmed: 30457077
Clin Drug Investig. 2016 Mar;36(3):169-75
pubmed: 26692007
Psychol Bull. 2016 Sep;142(9):969-990
pubmed: 27416139
Sr Care Pharm. 2019 Jul 1;34(7):419-431
pubmed: 31383052
CMAJ. 2007 Apr 24;176(9):1299-304
pubmed: 17452665
PLoS Med. 2018 Jun 18;15(6):e1002587
pubmed: 29912983
Ergonomics. 2005 Sep 15-Nov 15;48(11-14):1512-22
pubmed: 16338717
Sleep Med Rev. 2005 Feb;9(1):41-50
pubmed: 15649737
Cochrane Database Syst Rev. 2018 May 10;5:CD012455
pubmed: 29746721
J Am Geriatr Soc. 2004 Oct;52(10):1618-25
pubmed: 15450036
J Am Geriatr Soc. 2014 May;62(5):805-11
pubmed: 24749761
Exp Gerontol. 2005 Dec;40(12):911-25
pubmed: 16183237
Am J Geriatr Psychiatry. 2019 Jan;27(1):32-41
pubmed: 30409547
Gerontologist. 2007 Oct;47(5):662-71
pubmed: 17989408
Sleep Med Rev. 2017 Aug;34:10-22
pubmed: 28648359
J Clin Sleep Med. 2015 Oct 15;11(10):1199-236
pubmed: 26414986
Health Aff (Millwood). 2014 Apr;33(4):658-66
pubmed: 24711328
Psychiatry (Edgmont). 2008 May;5(5):34-48
pubmed: 19727251
Brain Res. 1995 Aug 7;688(1-2):77-85
pubmed: 8542325
J Am Geriatr Soc. 2001 Oct;49(10):1341-5
pubmed: 11890493
Curr Neuropharmacol. 2017;15(7):1010-1031
pubmed: 28294066